The present findings, showing that TRAIL-R3 and TRAIL-R4 were expressed at substantially lower levels than TRAIL-R1 and TRAIL-R2, are in agreement with this report and seem to exclude that this mechanism of resistance to TRAIL is active in NB tumours. Here, TNFRSF10D is linked to neoplasm.